Please login to the form below
New Accounts, September, 2009, PR & Med Ed
New pharmaceutical account wins notified to us by the winning agency for the period July to September 2009 inclusive
New pharmaceutical account wins notified to us by the winning agency for the period July to September 2009 inclusive:
| CLIENT | PRODUCT | THERAPEUTIC AREA | WINNING AGENCY |
| AstraZeneca | n/a | Non-small cell lung cancer | Medaxial Group |
| Biogen Idec | n/a | Neurology | Medaxial Group |
| EMD Serono | Undisclosed | Infertility | Medaxial Group |
| Enturia | ChloraPrep | Surgical skin preparation | Medaxial Group |
| GSK | new product | Haematology | Succinct Healthcare Communications |
| The Hesley Group | n/a | Corporate | Clew Communications |
| Idis | European and UK corporate | Corporate | Ogilvy Healthworld UK |
| LCNDG | n/a | Oncology | Succinct Healthcare Communications |
| Mundipharma International | BruTrans and Targin | Pain | Euro RSCG Life |
| Mundipharma International | n/a | Respiratory | Health 4 Brands |
| Mundipharma International | New product | Pain | Health 4 Brands |
| NECDAG | n/a | Oncology | Succinct Healthcare Communications and Consultancy |
| Nutricia Advanced Medical Nutrition | Respifor | COPD | Virgo HEALTH |
| Nutricia Advanced Medical Nutrition | Conference support | Cross-band | Virgo HEALTH |
Please note that inclusion in this table does not necessarily indicate exclusivity and other agencies may also be involved with some of the products listed in other ways, or in domestic, overseas or international markets.
To submit an entry for New Accounts, email new_accounts@pmlive.com
Share
Related Hub content
COVID-19 Updates and Daily News
Featured jobs
- Biogen delays filing of Alzheimer’s drug, which hits its share price
- Regeneron says antibody for COVID-19 could be ready this year
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Alnylam and Vir plan gene-silencing attack on COVID-19 virus
- Roche/Gilead tag team fights COVID-19 with Actemra/remdesivir
- Moderna to begin pivotal phase 3 trial of COVID-19 vaccine in July
- Impetus Digital Fireside Chat with Susanne Somerville of Chronicled
- Impetus Digital Fireside Chat with Bechara Saab of Mobio Interactive
- FDA delays review of Novartis’ MS drug ofatumumab
- Sanofi makes ‘best-in-class’ claim for Sarclisa in myeloma
- Q&A: Kay Wesley
PMHub
W2O Group
W2O Group is an integrated marketing agency with expertise in brand and digital strategy, creative development and communications services. We...
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
